1 |
Del, C. J., M. Lindqvist, M. Cuello, M. Backstrom, O. Cabrerra, J. Persson, O. Perez, and A. M. Harandi. 2010. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 28: 1193-1200.
DOI
ScienceOn
|
2 |
Cortesi, R., L. Ravani, F. Rinaldi, P. Marconi, M. Drechsler, M. Manservigi, R. Argnani, E. Menegatti, E. Esposito, and R. Manservigi. 2013. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes. Int. J. Pharm. 440: 229-237.
DOI
ScienceOn
|
3 |
Chiuppesi, F., L. Vannucci, L. A. De, M. Lai, B. Matteoli, G. Freer, R. Manservigi, L. Ceccherini-Nelli, F. Maggi, M. Bendinelli, and M. Pistello. 2012. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J. Virol. 86: 6563-6574.
DOI
|
4 |
Dudley, K. L., N. Bourne, and G. N. Milligan. 2000. Immune protection against HSV-2 in B-cell-deficient mice. Virology 270: 454-463.
DOI
ScienceOn
|
5 |
Morrison, L. A., L. Zhu, and L. G. Thebeau. 2001. Vaccineinduced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. J. Virol. 75: 1195-1204.
DOI
ScienceOn
|
6 |
Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057.
DOI
ScienceOn
|
7 |
Suryawanshi, A., T. Veiga-Parga, N. K. Rajasagi, P. B. Reddy, S. Sehrawat, S. Sharma, and B. T. Rouse. 2011. Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology. J. Immunol. 187: 1919-1930.
DOI
|
8 |
Lund, J. M., M. M. Linehan, N. Iijima, and A. Iwasaki. 2006. Cutting Edge: Plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J. Immunol. 177: 7510-7514.
DOI
|
9 |
Bryant-Hudson, K. M., and D. J. Carr. 2012. PD-L1-expressing dendritic cells contribute to viral resistance during acute HSV-1 infection. Clin. Dev. Immunol. 2012: 924619.
|
10 |
Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198: 513-520.
DOI
ScienceOn
|
11 |
Shen, H., and A. Iwasaki. 2006. A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODNbased vaginal microbicide. J. Clin. Invest. 116: 2237-2243.
DOI
ScienceOn
|
12 |
Mott, K. R., D. Underhill, S. L. Wechsler, T. Town, and H. Ghiasi. 2009. A role for the JAK-STAT1 pathway in blocking replication of HSV-1 in dendritic cells and macrophages. Virol. J. 6: 56.
DOI
ScienceOn
|
13 |
Swaminathan, S., X. Hu, X. Zheng, Y. Kriga, J. Shetty, Y. Zhao, R. Stephens, B. Tran, M. W. Baseler, J. Yang, R. A. Lempicki, D. Huang, H. C. Lane, and T. Imamichi. 2013. Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. Biochem. Biophys. Res. Commun. 434: 228-234.
DOI
ScienceOn
|
14 |
Mott, K. R., D. Gate, M. Zandian, S. J. Allen, N. K. Rajasagi, R. N. van, S. Chen, M. Arditi, B. T. Rouse, R. A. Flavell, T. Town, and H. Ghiasi. 2011. Macrophage IL-12p70 signaling prevents HSV-1-induced CNS autoimmunity triggered by autoaggressive Tregs. Invest Ophthalmol. Vis. Sci. 52: 2321-2333.
DOI
|
15 |
Zolini, G. P., G. K. Lima, N. Lucinda, M. A. Silva, M. F. Dias, N. L. Pessoa, B. P. Coura, C. T. Cartelle, R. M. Arantes, E. G. Kroon, and M. A. Campos. 2014. Defense against HSV-1 in a murine model is mediated by iNOS and orchestrated by the activation of TLR2 and TLR9 in trigeminal ganglia. J. Neuroinflammation. 11: 20.
DOI
ScienceOn
|
16 |
Wojtasiak, M., D. L. Pickett, M. D. Tate, S. L. Londrigan, S. Bedoui, A. G. Brooks, and P. C. Reading. 2010. Depletion of , but not , immune cells exacerbates virus replication and disease in an intranasal model of herpes simplex virus type 1 infection. J. Gen. Virol. 91: 2158-2166.
DOI
ScienceOn
|
17 |
Iijima, N., L. M. Mattei, and A. Iwasaki. 2011. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc. Natl. Acad. Sci. U. S. A 108: 284-289.
DOI
ScienceOn
|
18 |
Parr, M. B., and E. L. Parr. 2000. Immunity to vaginal herpes simplex virus-2 infection in B-cell knockout mice. Immunology 101: 126-131.
DOI
|
19 |
Milligan, G. N. 1999. Neutrophils aid in protection of the vaginal mucosae of immune mice against challenge with herpes simplex virus type 2. J. Virol. 73: 6380-6386.
|
20 |
Molesworth-Kenyon, S. J., N. Popham, A. Milam, J. E. Oakes, and R. N. Lausch. 2012. Resident corneal cells communicate with neutrophils leading to the production of IP-10 during the primary inflammatory response to HSV-1 infection. Int. J. Inflam. 2012: 810359.
|
21 |
Li, J., L. Ye, X. Wang, S. Hu, and W. Ho. 2012. Induction of interferon-gamma contributes to Toll-like receptor 3-mediated herpes simplex virus type 1 inhibition in astrocytes. J. Neurosci. Res. 90: 399-406.
DOI
ScienceOn
|
22 |
Ghiasi, H., S. Cai, G. C. Perng, A. B. Nesburn, and S. L. Wechsler. 2000. The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection. Antiviral Res. 45: 33-45.
DOI
ScienceOn
|
23 |
Lehmann, C., M. Zeis, and L. Uharek. 2001. Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells. Br. J. Haematol. 114: 660-665.
DOI
ScienceOn
|
24 |
Ashkar, A. A., and K. L. Rosenthal. 2003. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J. Virol. 77: 10168-10171.
DOI
ScienceOn
|
25 |
Kassim, S. H., N. K. Rajasagi, X. Zhao, R. Chervenak, and S. R. Jennings. 2006. In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses. J. Virol. 80: 3985-3993.
DOI
ScienceOn
|
26 |
Reading, P. C., P. G. Whitney, D. P. Barr, M. Wojtasiak, J. D. Mintern, J. Waithman, and A. G. Brooks. 2007. IL-18, but not IL-12, regulates NK cell activity following intranasal herpes simplex virus type 1 infection. J. Immunol. 179: 3214-3221.
DOI
|
27 |
Sato, A., and A. Iwasaki. 2004. Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. Proc. Natl. Acad. Sci. U. S. A 101: 16274-16279.
DOI
ScienceOn
|
28 |
Nandakumar, S., S. N. Woolard, D. Yuan, B. T. Rouse, and U. Kumaraguru. 2008. Natural killer cells as novel helpers in anti-herpes simplex virus immune response. J. Virol. 82: 10820-10831.
DOI
ScienceOn
|
29 |
Staats, H. F., J. E. Oakes, and R. N. Lausch. 1991. Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo cells. J. Virol. 65: 6008-6014.
|
30 |
Zhao, X., E. Deak, K. Soderberg, M. Linehan, D. Spezzano, J. Zhu, D. M. Knipe, and A. Iwasaki. 2003. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J. Exp. Med. 197: 153-162.
DOI
|
31 |
Reske, A., G. Pollara, C. Krummenacher, D. R. Katz, and B. M. Chain. 2008. Glycoprotein-dependent and TLR2-independent innate immune recognition of herpes simplex virus-1 by dendritic cells. J. Immunol. 180: 7525-7536.
DOI
|
32 |
Kassim, S. H., N. K. Rajasagi, B. W. Ritz, S. B. Pruett, E. M. Gardner, R. Chervenak, and S. R. Jennings. 2009. Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1. J. Virol. 83: 3175-3186.
DOI
ScienceOn
|
33 |
Wakimoto, H., P. R. Johnson, D. M. Knipe, and E. A. Chiocca. 2003. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10: 983-990.
DOI
ScienceOn
|
34 |
Frank, G. M., K. A. Buela, D. M. Maker, S. A. Harvey, and R. L. Hendricks. 2012. Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea. J. Immunol. 188: 1350-1359.
DOI
ScienceOn
|
35 |
Ellermann-Eriksen, S. 2005. Macrophages and cytokines in the early defence against herpes simplex virus. Virol. J. 2: 59.
DOI
ScienceOn
|
36 |
Verschoor, A., M. A. Brockman, D. M. Knipe, and M. C. Carroll. 2001. Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J. Immunol. 167: 2446-2451.
DOI
|
37 |
Chan, T., N. G. Barra, A. J. Lee, and A. A. Ashkar. 2011. Innate and adaptive immunity against herpes simplex virus type 2 in the genital mucosa. J. Reprod. Immunol. 88: 210-218.
DOI
ScienceOn
|
38 |
Kim, M., N. R. Osborne, W. Zeng, H. Donaghy, K. McKinnon, D. C. Jackson, and A. L. Cunningham. 2012. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes. J. Immunol. 188: 4158-4170.
DOI
ScienceOn
|
39 |
Harandi, A. M., B. Svennerholm, J. Holmgren, and K. Eriksson. 2001. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82: 845-853.
DOI
|
40 |
Da, C., X, M. A. Brockman, E. Alicot, M. Ma, M. B. Fischer, X. Zhou, D. M. Knipe, and M. C. Carroll. 1999. Humoral response to herpes simplex virus is complement-dependent. Proc. Natl. Acad. Sci. U. S. A. 96: 12708-12712.
DOI
|
41 |
Kwant-Mitchell, A., A. A. Ashkar, and K. L. Rosenthal. 2009. Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model. J. Virol. 83: 10664-10676.
DOI
ScienceOn
|
42 |
Bourne, K. Z., N. Bourne, S. F. Reising, and L. R. Stanberry. 1999. Plant products as topical microbicide candidates: assessment of in vitro and in vivo activity against herpes simplex virus type 2. Antiviral Res. 42: 219-226.
DOI
ScienceOn
|
43 |
Gebhardt, B. M., F. Focher, R. Eberle, A. Manikowski, and G. E. Wright. 2009. Effect of combinations of antiviral drugs on herpes simplex encephalitis. Drug Des Devel. Ther. 3: 289-294.
|
44 |
Mansur, D. S., E. G. Kroon, M. L. Nogueira, R. M. Arantes, S. C. Rodrigues, S. Akira, R. T. Gazzinelli, and M. A. Campos. 2005. Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1. Am. J. Pathol. 166: 1419-1426.
DOI
ScienceOn
|
45 |
Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors. Annu. Rev. Immunol. 21: 335-376.
DOI
ScienceOn
|
46 |
Roizman. B., and Knipe, D. M. 2001. Herpes simplex viruses and their replication. In Fields Virology, 4th edition. Eds. Knipe, D. M., and Howley, P. M. Lippincott Williams & Wilkins. p. 2399-2459.
|
47 |
Bernstein, D. I., and L. R. Stanberry. 1999. Herpes simplex virus vaccines. Vaccine 17: 1681-1689.
DOI
ScienceOn
|
48 |
Kawai, T., and S. Akira. 2005. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17: 338-344.
DOI
ScienceOn
|
49 |
Kawai, T., and S. Akira. 2007. TLR signaling. Cell Death Differ. 13: 816-825.
|
50 |
Doyle, S. L., and L. A. O'Neill. 2006. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 72: 1102-1113.
DOI
ScienceOn
|
51 |
Menasria, R., N. Boivin, M. Lebel, J. Piret, J. Gosselin, and G. Boivin. 2013. Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection. J. Virol. 87: 7301-7308.
DOI
ScienceOn
|
52 |
Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-459.
DOI
ScienceOn
|
53 |
Wang, J. P., G. N. Bowen, S. Zhou, A. Cerny, A. Zacharia, D. M. Knipe, R. W. Finberg, and E. A. Kurt-Jones. 2012. Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J. Virol. 86: 2273-2281.
DOI
|
54 |
Aravalli, R. N., S. Hu, T. N. Rowen, J. M. Palmquist, and J. R. Lokensgard. 2005. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J. Immunol. 175: 4189-4193.
DOI
|
55 |
Krug, A., G. D. Luker, W. Barchet, D. A. Leib, S. Akira, and M. Colonna. 2004. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 103: 1433-1437.
|
56 |
Schachtele, S. J., S. Hu, M. R. Little, and J. R. Lokensgard. 2010. Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2. J. Neuroinflammation. 7: 35.
DOI
ScienceOn
|
57 |
Hochrein, H., B. Schlatter, M. O'Keeffe, C. Wagner, F. Schmitz, M. Schiemann, S. Bauer, M. Suter, and H. Wagner. 2004. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc. Natl. Acad. Sci. U. S. A. 101: 11416-11421.
DOI
ScienceOn
|
58 |
Sorensen, L. N., L. S. Reinert, L. Malmgaard, C. Bartholdy, A. R. Thomsen, and S. R. Paludan. 2008. TLR2 and TLR9 synergistically control herpes simplex virus infection in the brain. J. Immunol. 181: 8604-8612.
DOI
|
59 |
Tengvall, S., and A. M. Harandi. 2008. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. J. Reprod. Immunol. 78: 49-57.
DOI
ScienceOn
|
60 |
Isaacs, A., J. Lindenmann, and R. C. Valentine. 1957. Virus interference. II. Some properties of interferon. Proc. R. Soc. Lond B Biol. Sci. 147: 268-273.
DOI
|
61 |
Guo, Y., M. Audry, M. Ciancanelli, L. Alsina, J. Azevedo, M. Herman, E. Anguiano, V. Sancho-Shimizu, L. Lorenzo, E. Pauwels, P. B. Philippe, D. R. Perez de, A. Cardon, G. Vogt, C. Picard, Z. Z. Andrianirina, F. Rozenberg, P. Lebon, S. Plancoulaine, M. Tardieu, D. Valerie, E. Jouanguy, D. Chaussabel, F. Geissmann, L. Abel, J. L. Casanova, and S. Y. Zhang. 2011. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208: 2083-2098.
DOI
ScienceOn
|
62 |
Reinert, L. S., L. Harder, C. K. Holm, M. B. Iversen, K. A. Horan, F. gnaes-Hansen, B. P. Ulhoi, T. H. Holm, T. H. Mogensen, T. Owens, J. R. Nyengaard, A. R. Thomsen, and S. R. Paludan. 2012. TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice. J. Clin. Invest 122: 1368-1376.
DOI
ScienceOn
|
63 |
Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. Shah, J. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77.
|
64 |
Swann, J. B., Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, P. Hertzog, and M. J. Smyth. 2007. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178: 7540-7549.
DOI
|
65 |
Liu, Y. J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23: 275-306.
DOI
ScienceOn
|
66 |
Janeway, C. A., Travers, P., Walport, M., and Shlomchik, M. J. 2005. Immunobiology. The immune system in health and disease, 6th Edition. Garland Science, New York, p. 461-516.
|
67 |
Conrady, C. D., W. P. Halford, and D. J. Carr. 2011. Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection. J. Virol. 85: 1625-1633.
DOI
ScienceOn
|
68 |
Sheppard, P., W. Kindsvogel, W. Xu, K. Henderson, S. Schlutsmeyer, T. E. Whitmore, R. Kuestner, U. Garrigues, C. Birks, J. Roraback, C. Ostrander, D. Dong, J. Shin, S. Presnell, B. Fox, B. Haldeman, E. Cooper, D. Taft, T. Gilbert, F. J. Grant, M. Tackett, W. Krivan, G. McKnight, C. Clegg, D. Foster, and K. M. Klucher. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68.
DOI
ScienceOn
|
69 |
Gill, N., P. M. Deacon, B. Lichty, K. L. Mossman, and A. A. Ashkar. 2006. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production. J. Virol. 80: 9943-9950.
DOI
ScienceOn
|
70 |
Rasmussen, S. B., L. N. Sorensen, L. Malmgaard, N. Ank, J. D. Baines, Z. J. Chen, and S. R. Paludan. 2007. Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J. Virol. 81: 13315-13324.
DOI
ScienceOn
|
71 |
Milligan, G. N., and D. I. Bernstein. 1997. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229: 259-268.
DOI
ScienceOn
|
72 |
Conrady, C. D., H. Jones, M. Zheng, and D. J. Carr. 2011. A functional type I interferon pathway drives resistance to cornea herpes simplex virus type 1 infection by recruitment of leukocytes. J. Biomed. Res. 25: 111-119.
DOI
ScienceOn
|
73 |
Conrady, C. D., M. Zheng, N. A. Mandal, R. N. van, and D. J. Carr. 2013. IFN-alpha-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal. Immunol. 6: 45-55.
DOI
ScienceOn
|
74 |
Gill, N., M. J. Chenoweth, E. F. Verdu, and A. A. Ashkar. 2011. NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection. Cell Immunol. 269: 29-37.
DOI
ScienceOn
|
75 |
Doyle, S. E., H. Schreckhise, K. Khuu-Duong, K. Henderson, R. Rosler, H. Storey, L. Yao, H. Liu, F. Barahmand-pour, P. Sivakumar, C. Chan, C. Birks, D. Foster, C. H. Clegg, P. Wietzke-Braun, S. Mihm, and K. M. Klucher. 2006. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
DOI
ScienceOn
|
76 |
Mikloska, Z., and A. L. Cunningham. 2001. Alpha and gamma interferons inhibit herpes simplex virus type 1 infection and spread in epidermal cells after axonal transmission. J. Virol. 75: 11821-11826.
DOI
ScienceOn
|
77 |
Dobbs, M. E., J. E. Strasser, C. F. Chu, C. Chalk, and G. N. Milligan. 2005. Clearance of herpes simplex virus type 2 by T cells requires gamma interferon and either perforin-or Fas-mediated cytolytic mechanisms. J. Virol. 79: 14546-14554.
DOI
ScienceOn
|
78 |
Cantin, E., B. Tanamachi, and H. Openshaw. 1999. Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J. Virol. 73: 3418-3423.
|
79 |
Zhou, Z., O. J. Hamming, N. Ank, S. R. Paludan, A. L. Nielsen, and R. Hartmann. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81: 7749-7758.
DOI
ScienceOn
|
80 |
Stanberry, L. R., D. I. Bernstein, R. L. Burke, C. Pachl, and M. G. Myers. 1987. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155: 914-920.
DOI
ScienceOn
|
81 |
Zhang, X., A. A. Chentoufi, G. Dasgupta, A. B. Nesburn, M. Wu, X. Zhu, D. Carpenter, S. L. Wechsler, S. You, and L. BenMohamed. 2009. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic T cells and protects against herpes simplex virus type 2 challenge. Mucosal. Immunol. 2: 129143.
|
82 |
Iversen, M. B., N. Ank, J. Melchjorsen, and S. R. Paludan. 2010. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J. Virol. 84: 4579-4586.
DOI
ScienceOn
|
83 |
Marcello, T., A. Grakoui, G. Barba-Spaeth, E. S. Machlin, S. V. Kotenko, M. R. MacDonald, and C. M. Rice. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898.
DOI
ScienceOn
|
84 |
Ank, N., H. West, C. Bartholdy, K. Eriksson, A. R. Thomsen, and S. R. Paludan. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80: 4501-4509.
DOI
ScienceOn
|
85 |
Ank, N., M. B. Iversen, C. Bartholdy, P. Staeheli, R. Hartmann, U. B. Jensen, F. gnaes-Hansen, A. R. Thomsen, Z. Chen, H. Haugen, K. Klucher, and S. R. Paludan. 2008. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 180: 2474-2485.
DOI
|
86 |
Li, J., S. Hu, L. Zhou, L. Ye, X. Wang, J. Ho, and W. Ho. 2011. Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia 59: 58-67.
DOI
ScienceOn
|
87 |
Bourne, N., F. J. Bravo, M. Francotte, D. I. Bernstein, M. G. Myers, M. Slaoui, and L. R. Stanberry. 2003. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 187: 542-549.
DOI
ScienceOn
|
88 |
Jamali, A., M. H. Roostaee, H. Soleimanjahi, P. F. Ghaderi, and T. Bamdad. 2007. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge. Comp Immunol. Microbiol. Infect. Dis. 30: 71-80.
DOI
ScienceOn
|
89 |
Johnston, C., D. M. Koelle, and A. Wald. 2011. HSV-2: in pursuit of a vaccine. J. Clin. Invest 121: 4600-4609.
DOI
|
90 |
Belshe, R. B., P. A. Leone, D. I. Bernstein, A. Wald, M. J. Levin, J. T. Stapleton, I. Gorfinkel, R. L. Morrow, M. G. Ewell, A. Stokes-Riner, G. Dubin, T. C. Heineman, J. M. Schulte, and C. D. Deal. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366: 3443.
|
91 |
Ghasemi, M., M. Erturk, K. Buruk, and M. Sonmez. 2013. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells. Cytotherapy 15: 352-361.
DOI
ScienceOn
|
92 |
Bourne, N., G. N. Milligan, L. R. Stanberry, R. Stegall, and R. B. Pyles. 2005. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J. Infect. Dis. 192: 2117-2123.
DOI
ScienceOn
|
93 |
Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347: 1652-1661.
DOI
ScienceOn
|
94 |
Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, and S. E. Straus. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282: 331-340.
|
95 |
Ushio, C., H. Ariyasu, T. Ariyasu, S. Arai, T. Ohta, and S. Fukuda. 2009. Suppressive effects of a cyanine dye against herpes simplex virus (HSV)-1 infection. Biomed. Res. 30: 365-368.
DOI
|
96 |
Kim, S. B., Y. W. Han, M. M. Rahman, S. J. Kim, D. J. Yoo, S. H. Kang, K. Kim, and S. K. Eo. 2009. Modulation of protective immunity against herpes simplex virus via mucosal genetic co-transfer of DNA vaccine with beta2-adrenergic agonist. Exp. Mol. Med. 41: 812-823.
DOI
ScienceOn
|
97 |
Lindqvist, M., J. Persson, K. Thorn, and A. M. Harandi. 2009. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182: 6435-6443.
DOI
ScienceOn
|
98 |
Uyangaa, E., H. K. Lee, and S. K. Eo. 2012. Glutamine and leucine provide enhanced protective immunity against mucosal infection with herpes simplex virus type 1. Immune. Netw. 12: 196-206.
DOI
ScienceOn
|
99 |
Kuo, Y. C., Y. C. Lee, Y. L. Leu, W. J. Tsai, and S. C. Chang. 2008. Efficacy of orally administered Lobelia chinensis extracts on herpes simplex virus type 1 infection in BALB/c mice. Antiviral Res. 80: 206-212.
DOI
ScienceOn
|
100 |
Cho, A., Y. S. Roh, E. Uyangaa, S. Park, J. W. Kim, K. H. Lim, J. Kwon, S. K. Eo, C. W. Lim, and B. Kim. 2013. Protective effects of red ginseng extract against vaginal herpes simplex virus infection. J. Ginseng. Res. 37: 210-218.
DOI
ScienceOn
|
101 |
Petrera, E., and C. E. Coto. 2014. Effect of the potent antiviral 1-cinnamoyl-3,11-dihydroxymeliacarpin on cytokine production by murine macrophages stimulated with HSV-2. Phytother. Res. 28: 104-109.
DOI
ScienceOn
|
102 |
Balzarini, J., G. Andrei, E. Balestra, D. Huskens, C. Vanpouille, A. Introini, S. Zicari, S. Liekens, R. Snoeck, A. Holy, C. F. Perno, L. Margolis, and D. Schols. 2013. A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity. PLoS Pathog. 9: e1003456.
DOI
|
103 |
Hu, K., X. He, F. Yu, X. Yuan, W. Hu, C. Liu, F. Zhao, and J. Dou. 2011. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis. Immunol. Invest 40: 265-278.
|
104 |
Koelle, D. M., A. Magaret, C. L. McClurkan, M. L. Remington, T. Warren, F. Teofilovici, and A. Wald. 2008. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects. Clin. Vaccine Immunol. 15: 773-782.
DOI
ScienceOn
|
105 |
Awasthi, S., J. W. Balliet, J. A. Flynn, J. M. Lubinski, C. E. Shaw, D. J. DiStefano, M. Cai, M. Brown, J. F. Smith, R. Kowalski, R. Swoyer, J. Galli, V. Copeland, S. Rios, R. C. Davidson, M. Salnikova, S. Kingsley, J. Bryan, D. R. Casimiro, and H. M. Friedman. 2014. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J. Virol. 88: 2000-2010.
DOI
ScienceOn
|
106 |
Brans, R., and F. Yao. 2010. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC. Microbiol. 10: 163.
DOI
ScienceOn
|
107 |
Koelle, D. M., and L. Corey. 2008. Herpes simplex: insights on pathogenesis and possible vaccines. Annu. Rev. Med. 59: 381-395.
DOI
ScienceOn
|
108 |
Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank, and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest 101: 1500-1508.
DOI
ScienceOn
|
109 |
Himmelein, S., A. J. St Leger, J. E. Knickelbein, A. Rowe, M. L. Freeman, and R. L. Hendricks. 2011. Circulating herpes simplex type 1 (HSV-1)-specific T cells do not access HSV-1 latently infected trigeminal ganglia. Herpesviridae. 2: 5.
DOI
ScienceOn
|
110 |
Wilson, S. S., E. Fakioglu, and B. C. Herold. 2009. Novel approaches in fighting herpes simplex virus infections. Expert. Rev. Anti. Infect. Ther. 7: 559-568.
DOI
ScienceOn
|
111 |
Petrera, E., and C. E. Coto. 2014. Effect of the potent antiviral 1-cinnamoyl-3,11-dihydroxymeliacarpin on cytokine production by murine macrophages stimulated with HSV-2. Phytother. Res. 28: 104-109.
DOI
ScienceOn
|
112 |
Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
DOI
ScienceOn
|
113 |
Boivin, N., Y. Sergerie, S. Rivest, and G. Boivin. 2008. Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis. J. Infect. Dis. 198: 664672.
|
114 |
Miller, R. L., M. A. Tomai, C. J. Harrison, and D. I. Bernstein. 2002. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int. Immunopharmacol. 2: 443-451.
DOI
ScienceOn
|
115 |
Ashkar, A. A., X. D. Yao, N. Gill, D. Sajic, A. J. Patrick, and K. L. Rosenthal. 2004. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190: 1841-1849.
DOI
ScienceOn
|
116 |
Sajic, D., A. J. Patrick, and K. L. Rosenthal. 2005. Mucosal delivery of CpG oligodeoxynucleotides expands functional dendritic cells and macrophages in the vagina. Immunology 114: 213-224.
DOI
ScienceOn
|
117 |
Ashkar, A. A., S. Bauer, W. J. Mitchell, J. Vieira, and K. L. Rosenthal. 2003. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77: 8948-8956.
DOI
|
118 |
Gill, N., E. J. Davies, and A. A. Ashkar. 2008. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am. J. Reprod. Immunol. 59: 35-43.
|
119 |
Tumpey, T. M., H. Cheng, X. T. Yan, J. E. Oakes, and R. N. Lausch. 1998. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J. Leukoc. Biol. 63: 486-492.
DOI
|
120 |
Kratholm, S. K., M. B. Iversen, L. Reinert, S. K. Jensen, M. Hokland, T. Andersen, A. Rankin, D. Young, S. Frische, S. R. Paludan, and C. K. Holm. 2013. Interleukin-21 receptor signalling is important for innate immune protection against HSV-2 infections. PLoS One 8: e81790.
DOI
|
121 |
Eo, S. K., S. Lee, S. Chun, and B. T. Rouse. 2001. Modulation of immunity against herpes simplex virus infection via mucosal genetic transfer of plasmid DNA encoding chemokines. J. Virol. 75: 569-578.
DOI
ScienceOn
|
122 |
Ghiasi, H., S. Cai, G. C. Perng, A. B. Nesburn, and S. L. Wechsler. 2000. Both and T cells are involved in protection against HSV-1 induced corneal scarring. Br. J. Ophthalmol. 84: 408-412.
DOI
|
123 |
Kumamoto, Y., L. M. Mattei, S. Sellers, G. W. Payne, and A. Iwasaki. 2011. T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc. Natl. Acad. Sci. U. S. A. 108: 8749-8754.
DOI
ScienceOn
|
124 |
Coleman, C. A., M. C. Muller-Trutwin, C. Apetrei, and I. Pandrea. 2007. T regulatory cells: aid or hindrance in the clearance of disease? J. Cell Mol. Med. 11: 1291-1325.
DOI
ScienceOn
|
125 |
Rajasagi, N. K. 2007. The role of Helper T cells, IL-2 and IL-15 in the generation of an optimal T cell response following infection with herpes simplex virus-1 (HSV-1). Louisiana State University Health Sciences Center-Shreveport, ProQuest, UMI Dissertations Publishing Number: 3311956, p. 56-61.
|
126 |
Koelle, D. M., C. M. Posavad, G. R. Barnum, M. L. Johnson, J. M. Frank, and L. Corey. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest 101: 1500-1508.
DOI
ScienceOn
|
127 |
Dasgupta, G., A. A. Chentoufi, S. You, P. Falatoonzadeh, L. A. Urbano, A. Akhtarmalik, K. Nguyen, L. Ablabutyan, A. B. Nesburn, and L. BenMohamed. 2011. Engagement of TLR2 reverses the suppressor function of conjunctiva ![$CD4^+$ $CD4^+$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$CD4^+$}) regulatory T cells and promotes herpes simplex virus epitope-specific ![$CD4^+$ $CD4^+$](http://ocean.kisti.re.kr/cgi-bin/mimetex.cgi?\small{$CD4^+$}) effector T cell responses. Invest Ophthalmol. Vis. Sci. 52: 3321-3333.
DOI
|
128 |
Sehrawat, S., S. Suvas, P. P. Sarangi, A. Suryawanshi, and B. T. Rouse. 2008. In vitro-generated antigen-specific regulatory T cells control the severity of herpes simplex virus-induced ocular immunoinflammatory lesions. J. Virol. 82: 6838-6851.
DOI
ScienceOn
|
129 |
Kim, J. O., H. R. Cha, E. D. Kim, and M. N. Kweon. 2012. Pathological effect of IL-17A-producing TCRgammadelta(+) T cells in mouse genital mucosa against HSV-2 infection. Immunol. Lett. 147: 34-40.
DOI
ScienceOn
|
130 |
Gorander, S., A. M. Harandi, M. Lindqvist, T. Bergstrom, and J. A. Liljeqvist. 2012. Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease. J. Virol. 86: 7544-7553.
DOI
|
131 |
Jirmo, A. C., C. H. Nagel, C. Bohnen, B. Sodeik, and G. M. Behrens. 2009. Contribution of direct and cross-presentation to CTL immunity against herpes simplex virus 1. J. Immunol. 182: 283-292.
DOI
|
132 |
St Leger, A. J., B. Peters, J. Sidney, A. Sette, and R. L. Hendricks. 2011. Defining the herpes simplex virus-specific T cell repertoire in C57BL/6 mice. J. Immunol. 186: 3927-3933.
DOI
|
133 |
van, L. A., M. Ayers, A. G. Brooks, R. M. Coles, W. R. Heath, and F. R. Carbone. 2004. Herpes simplex virus-specific T cells can clear established lytic infections from skin and nerves and can partially limit the early spread of virus after cutaneous inoculation. J. Immunol. 172: 392-397.
DOI
|
134 |
Liu, K., D. Jiang, L. Zhang, Z. Yao, Z. Chen, S. Yu, and X. Wang. 2012. Identification of B- and T-cell epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their immunogenicity and protection efficacy. Vaccine 30: 3034-3041.
DOI
ScienceOn
|
135 |
Deshpande, S. P., M. Zheng, M. Daheshia, and B. T. Rouse. 2000. Pathogenesis of herpes simplex virus-induced ocular immunoinflammatory lesions in B-cell-deficient mice. J. Virol. 74: 3517-3524.
DOI
|
136 |
Peek, R., G. M. Verjans, and B. Meek. 2002. Herpes simplex virus infection of the human eye induces a compartmentalized virus-specific B cell response. J. Infect. Dis. 186: 1539-1546.
DOI
ScienceOn
|
137 |
Iijima, N., M. M. Linehan, M. Zamora, D. Butkus, R. Dunn, M. R. Kehry, T. M. Laufer, and A. Iwasaki. 2008. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 205: 3041-3052.
DOI
ScienceOn
|
138 |
Kuklin, N. A., M. Daheshia, S. Chun, and B. T. Rouse. 1998. Role of mucosal immunity in herpes simplex virus infection. J. Immunol. 160: 5998-6003.
|